News & Updates
Filter by Specialty:

Neoadjuvant nivolumab plus chemo: New SoC in resectable NSCLC
13 May 2022
byChristina Lau
In patients with resectable non-small-cell lung cancer (NSCLC), neoadjuvant nivolumab in combination with platinum-based chemotherapy significantly improves event-free survival (EFS) and shows a trend towards better overall survival (OS) vs chemotherapy alone, without impeding the feasibility of surgery or increasing adverse events (AEs), according to results of the phase III CheckMate 816 trial.
Neoadjuvant nivolumab plus chemo: New SoC in resectable NSCLC
13 May 2022
SWOG S1616 suggests PFS benefit with ipi-nivo combo in metastatic/unresectable melanoma
12 May 2022
byRoshini Claire Anthony
The combination of ipilimumab and nivolumab may provide a progression-free survival (PFS) benefit in patients with metastatic or unresectable melanoma who did not respond to anti-PD-1/anti-PD-L1 therapy, according to a small study presented at AACR 2022.